DCR-PDL1
/ Novo Nordisk
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 07, 2025
Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
(clinicaltrials.gov)
- P1 | N=32 | Recruiting | Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Trial primary completion date: Jun 2025 ➔ Jun 2026
Trial primary completion date • Solid Tumor • PD-L1
July 16, 2024
Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
(clinicaltrials.gov)
- P1 | N=32 | Recruiting | Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
New P1 trial • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1